NCT06751329

Who might be able to join this trial:

• You are 18 years of age or older at the time of signing the consent form.
• You are able to understand and willing to sign a written consent form agreeing to take part.
• You are reasonably active and able to care for yourself, with limited or no restriction on daily activities (based on a standard cancer performance scale scoring 0, 1, or 2).
• Doctors expect you to live for at least 3 more months.
• Your recent blood test results (taken within 7 days before starting the study drug) meet specific healthy ranges for blood cell counts, kidney function, liver function, and blood clotting — your doctor will check these for you.
• You have cancer that can be measured on a scan, following standard measurement guidelines.
• You are able to provide a tumor tissue sample taken within the last 3 years (if a new biopsy is not possible, the trial team should be contacted, as this may still be discussed).

Who may not be able to join:

• You have had another active invasive cancer in the past 5 years (some exceptions may apply, such as certain skin cancers or non-invasive cancers that were fully treated — confirm with trial site).
• You have, or have had, a blood cancer (such as leukemia or lymphoma).
• You have received cancer treatments such as chemotherapy, immunotherapy, targeted therapy, or radiation recently — specific waiting periods apply depending on the treatment type (confirm exact timeframes with trial site).
• You have had major surgery within the last 4 weeks.
• You have cancer that started in the brain or has spread to the brain, unless it has been treated, is not growing, and you have been off high-dose steroids for at least 4 weeks.
• You have had a serious allergic reaction to a type of cancer drug called an antibody-drug conjugate (ADC), or you previously had to stop an ADC drug due to serious side effects.
• You have previously been treated with a specific type of ADC drug that uses a "topoisomerase I" component (confirm with trial site).
• You have taken an experimental drug within the past 4 weeks.
• You have an active, uncontrolled infection that requires intravenous (IV) antibiotics, antiviral, or antifungal treatment.
• You have a significant pre-existing lung condition (such as lung scarring, inflammation, or severe radiation-related lung damage) or a serious pre-existing eye condition.
• You have other serious uncontrolled health conditions, such as uncontrolled heart disease, immune disorders, diabetes, fluid build-up around the lungs or abdomen, or a mental health condition that would make it hard to follow the study requirements.
• Your heart's electrical activity shows a certain abnormality on an ECG (a heart tracing test) known as a prolonged QTc interval, or you are taking medicines known to affect this (confirm with trial site).
• Your heart's pumping strength is below 50%, as measured by a heart scan taken within the past 28 days.
• You have an active hepatitis B or hepatitis C infection (some people who are chronic carriers of hepatitis B or who have been successfully treated for hepatitis C may still be eligible — confirm with trial site).
• You have HIV that is not well controlled (people with well-controlled HIV meeting specific criteria may still be eligible — confirm with trial site).
• You have active tuberculosis (TB); if you are from a country where TB is common, you will be screened for it before joining.
• You have received a live vaccine within the past 30 days before starting the study drug.
• You still have significant side effects from previous cancer treatments that have not returned to a mild or baseline level (some stable, long-standing mild side effects may be acceptable — confirm with trial site).
• You are currently pregnant, breastfeeding, or planning to become pregnant during the study.
• You are able to have children but are unwilling to use effective contraception during the study and for up to 7 months after the last dose (for women) or 4 months (for men).
• You have taken certain medicines or foods that strongly affect how the body processes a specific liver enzyme (CYP3A4/5) within 2 weeks before starting the study drug (confirm specific substances with trial site).

Important: Always verify eligibility with the trial site directly before applying.